Literature DB >> 2327750

Pharmacokinetics of lomefloxacin in healthy volunteers: comparison of 400 milligrams once daily and 200 milligrams twice daily given orally for 5 days.

I Gros1, C Carbon.   

Abstract

We evaluated the effect of repeated oral doses (5 days of treatment) on the kinetics of lomefloxacin in volunteers and compared the kinetics after two different regimens, i.e., 400 mg once daily and 200 mg twice daily. After 400 mg of lomefloxacin was given once daily, no significant modification in the pharmacokinetic parameters was noted between the first and the fifth dose (maximum concentration of drug in serum, about 4 mg/liter; elimination half-life, about 6.3 h). After a dose of 200 mg every 12 h, a significant increase in the minimum concentration of drug in serum (0.49 +/- 0.1 and 0.72 +/- 0.2 mg/litter at days 1 and 5, respectively) and the area under the concentration-time curve (about 20%) was noted. The 400-mg regimen is probably adequate for therapeutic use.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2327750      PMCID: PMC171537          DOI: 10.1128/AAC.34.1.150

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  6 in total

1.  In vitro and in vivo activity of NY-198, a new difluorinated quinolone.

Authors:  T Hirose; E Okezaki; H Kato; Y Ito; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

2.  Pharmacokinetics and tolerance of lomefloxacin after sequentially increasing oral doses.

Authors:  P J Morrison; T G Mant; G T Norman; J Robinson; R L Kunka
Journal:  Antimicrob Agents Chemother       Date:  1988-10       Impact factor: 5.191

3.  Pharmacokinetics and tissue penetration of orally administered lomefloxacin.

Authors:  J W Stone; J M Andrews; J P Ashby; D Griggs; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1988-10       Impact factor: 5.191

4.  In vitro activity of lomefloxacin, a new quinolone antimicrobial agent, in comparison with those of other agents.

Authors:  R Wise; J M Andrews; J P Ashby; R S Matthews
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

5.  In vitro activity of lomefloxacin (SC-47111; NY-198), a difluoroquinolone 3-carboxylic acid, compared with those of other quinolones.

Authors:  N X Chin; A Novelli; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

Review 6.  Clinical pharmacokinetics of the newer antibacterial 4-quinolones.

Authors:  M Neuman
Journal:  Clin Pharmacokinet       Date:  1988-02       Impact factor: 6.447

  6 in total
  7 in total

Review 1.  Lomefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A N Wadworth; K L Goa
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

2.  Lack of interaction between lomefloxacin and caffeine in normal volunteers.

Authors:  D P Healy; J R Schoenle; J Stotka; R E Polk
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

Review 3.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

4.  Steady-state pharmacokinetics and sputum penetration of lomefloxacin in patients with chronic obstructive pulmonary disease and acute respiratory tract infections.

Authors:  J M Kovarik; A I Hoepelman; J M Smit; P A Sips; M Rozenberg-Arska; J H Glerum; J Verhoef
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

Review 5.  Lomefloxacin clinical pharmacokinetics.

Authors:  C D Freeman; D P Nicolau; P P Belliveau; C H Nightingale
Journal:  Clin Pharmacokinet       Date:  1993-07       Impact factor: 6.447

Review 6.  Future directions in antimicrobial chemotherapy.

Authors:  R Janknegt
Journal:  Pharm Weekbl Sci       Date:  1992-08-21

Review 7.  Absorption interactions with fluoroquinolones. 1995 update.

Authors:  B M Lomaestro; G R Bailie
Journal:  Drug Saf       Date:  1995-05       Impact factor: 5.606

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.